Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Price Target at $365.79

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has received an average rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $365.7857.

A number of research firms have recently weighed in on ONC. Jefferies Financial Group reaffirmed a “buy” rating and set a $420.00 price objective on shares of BeOne Medicines in a research report on Monday, November 17th. Morgan Stanley lifted their price target on shares of BeOne Medicines from $350.00 to $383.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Citizens Jmp upped their price target on shares of BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Truist Financial set a $400.00 price objective on shares of BeOne Medicines in a research report on Monday, November 24th. Finally, Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 3rd.

Insider Transactions at BeOne Medicines

In related news, SVP Chan Henry Lee sold 10,671 shares of the stock in a transaction dated Wednesday, October 8th. The stock was sold at an average price of $350.40, for a total transaction of $3,739,118.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lai Wang sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $350.06, for a total value of $1,750,300.00. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 81,094 shares of company stock valued at $27,929,161. 6.62% of the stock is owned by corporate insiders.

Institutional Trading of BeOne Medicines

Several hedge funds have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC boosted its position in shares of BeOne Medicines by 4.1% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock valued at $436,000 after acquiring an additional 50 shares during the last quarter. Penserra Capital Management LLC increased its position in BeOne Medicines by 2.7% in the third quarter. Penserra Capital Management LLC now owns 2,981 shares of the company’s stock worth $1,015,000 after purchasing an additional 79 shares during the last quarter. Allianz Asset Management GmbH lifted its position in BeOne Medicines by 3.0% during the third quarter. Allianz Asset Management GmbH now owns 3,400 shares of the company’s stock valued at $1,158,000 after purchasing an additional 100 shares during the last quarter. Blue Trust Inc. lifted its position in BeOne Medicines by 11.7% during the third quarter. Blue Trust Inc. now owns 967 shares of the company’s stock valued at $329,000 after purchasing an additional 101 shares during the last quarter. Finally, Anchor Investment Management LLC purchased a new position in shares of BeOne Medicines in the 2nd quarter worth $26,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Stock Performance

ONC opened at $322.90 on Friday. The company’s 50 day moving average is $332.85 and its 200 day moving average is $303.19. The company has a market cap of $38.28 billion, a price-to-earnings ratio of 633.14 and a beta of 0.45. BeOne Medicines has a 12-month low of $170.99 and a 12-month high of $385.22. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.